Viral Vector Solutions That Move Your Program Forward

Navigating the complexities of viral vector manufacturing requires scalable, flexible solutions that seamlessly bridge the gap between early-stage development and commercial production. Advanced platforms for AAV, lentivirus, and adenovirus utilize optimized adherent and suspension processes—reaching volumes up to 1,000 liters—to maximize yields and ensure robust, high-quality drug substance production.

To minimize product loss for high-value, small-volume therapies, specialized aseptic fill and finish operations are tightly integrated with phase-appropriate quality assurance programs. Facilities designed by former regulators support both clinical and commercial supply, streamlining the path to market. With accelerated onboarding timelines and direct access to technical leads, therapeutic innovators gain a transparent, digitally tracked manufacturing footprint.

Explore the complete brochure to discover how these integrated CDMO capabilities can optimize your viral vector program.